FRNM
Freenome, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NeutralFreenome reported strong Q3 2026 results with $1.10 EPS driven by FDA approval of SimpleScreen CRC and a collaboration agreement (likely Abbott), plus promising lung cancer screening data with FDA Breakthrough Designation. However, Q4 revenue guidance of only $2–4M signals minimal near-term commercialization, and the stock has declined significantly below its 200-day moving average despite fundamental progress, suggesting market skepticism about execution or competitive positioning.
Red flags
- •Minimal Q4 2026 revenue guidance ($2–4M) despite recent FDA approvals and partnerships, indicating slow commercial ramp
- •No meaningful testing revenue or royalties expected in Q4, raising questions about market adoption and revenue timing
- •Stock trading at 52-week lows despite positive Q3 earnings and product milestones, suggesting investor doubt about valuation or execution risk
- •Heavy reliance on future milestone payments ($70M contingent on Abbott transfer expected H1 2028) with significant execution risk
- •Major shareholder Highbridge Capital Management exited position entirely (8.1% to 0%), signaling insider lack of confidence
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).